NO334437B1 - Mikroporering av menneskehud for medikamentavlevering og overvåkningsanvendelser - Google Patents

Mikroporering av menneskehud for medikamentavlevering og overvåkningsanvendelser Download PDF

Info

Publication number: NO334437B1
Authority: NO; Norway
Prior art keywords: skin; stratum corneum; energy; micropore; tissue
Prior art date: 1995-08-29

Application number

NO19980878A

Other languages

English (en)

Norwegian (no)

Other versions

NO980878D0 (no

NO980878L (no

Inventor

Jonathan A Eppstein

Michael R Hatch

Difei Yang

Original Assignee

Spectrx Inc

Altea Therapeutics Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-08-29

Filing date

1998-02-27

Publication date

2014-03-03

1998-02-27 Application filed by Spectrx Inc, Altea Therapeutics Corp filed Critical Spectrx Inc

1998-02-27 Publication of NO980878D0 publication Critical patent/NO980878D0/no

1998-04-27 Publication of NO980878L publication Critical patent/NO980878L/no

2014-03-03 Publication of NO334437B1 publication Critical patent/NO334437B1/no

Links

238000012544 monitoring process Methods 0.000 title description 19
238000012377 drug delivery Methods 0.000 title description 8
210000003491 skin Anatomy 0.000 claims abstract description 220
210000000434 stratum corneum Anatomy 0.000 claims abstract description 196
238000010438 heat treatment Methods 0.000 claims abstract description 46
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 42
238000002844 melting Methods 0.000 claims abstract description 17
230000008018 melting Effects 0.000 claims abstract description 16
210000001519 tissue Anatomy 0.000 claims description 105
210000003722 extracellular fluid Anatomy 0.000 claims description 73
238000001816 cooling Methods 0.000 claims description 24
230000002829 reductive effect Effects 0.000 claims description 18
239000007787 solid Substances 0.000 claims description 17
239000000203 mixture Substances 0.000 claims description 15
239000011148 porous material Substances 0.000 claims description 14
230000035807 sensation Effects 0.000 claims description 14
230000001965 increasing effect Effects 0.000 claims description 11
230000008859 change Effects 0.000 claims description 10
238000012546 transfer Methods 0.000 claims description 9
239000003795 chemical substances by application Substances 0.000 claims description 5
238000004520 electroporation Methods 0.000 claims description 5
230000004907 flux Effects 0.000 claims description 5
238000004891 communication Methods 0.000 claims description 3
238000000034 method Methods 0.000 abstract description 114
239000000126 substance Substances 0.000 abstract description 56
239000003814 drug Substances 0.000 abstract description 49
239000012491 analyte Substances 0.000 abstract description 43
239000003623 enhancer Substances 0.000 abstract description 37
239000012530 fluid Substances 0.000 abstract description 21
230000035699 permeability Effects 0.000 abstract description 8
230000001225 therapeutic effect Effects 0.000 abstract description 7
230000003628 erosive effect Effects 0.000 abstract 1
239000008103 glucose Substances 0.000 description 94
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 93
210000004027 cell Anatomy 0.000 description 67
239000000975 dye Substances 0.000 description 67
210000002615 epidermis Anatomy 0.000 description 60
239000000523 sample Substances 0.000 description 59
210000004369 blood Anatomy 0.000 description 55
239000008280 blood Substances 0.000 description 55
239000010410 layer Substances 0.000 description 52
229940079593 drug Drugs 0.000 description 48
150000001875 compounds Chemical class 0.000 description 47
RBTKNAXYKSUFRK-UHFFFAOYSA-N heliogen blue Chemical compound [Cu].[N-]1C2=C(C=CC=C3)C3=C1N=C([N-]1)C3=CC=CC=C3C1=NC([N-]1)=C(C=CC=C3)C3=C1N=C([N-]1)C3=CC=CC=C3C1=N2 RBTKNAXYKSUFRK-UHFFFAOYSA-N 0.000 description 39
238000002679 ablation Methods 0.000 description 36
230000000694 effects Effects 0.000 description 34
238000012360 testing method Methods 0.000 description 28
238000002604 ultrasonography Methods 0.000 description 28
239000000243 solution Substances 0.000 description 27
230000006378 damage Effects 0.000 description 23
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 21
238000004088 simulation Methods 0.000 description 21
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 20
230000008569 process Effects 0.000 description 19
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
230000003287 optical effect Effects 0.000 description 18
238000010521 absorption reaction Methods 0.000 description 17
239000012528 membrane Substances 0.000 description 16
238000009826 distribution Methods 0.000 description 15
210000004379 membrane Anatomy 0.000 description 15
210000004207 dermis Anatomy 0.000 description 14
238000009792 diffusion process Methods 0.000 description 13
239000012153 distilled water Substances 0.000 description 13
230000006870 function Effects 0.000 description 13
239000000835 fiber Substances 0.000 description 12
239000007788 liquid Substances 0.000 description 12
208000002193 Pain Diseases 0.000 description 11
230000004888 barrier function Effects 0.000 description 11
238000001704 evaporation Methods 0.000 description 11
231100000862 numbness Toxicity 0.000 description 11
230000036407 pain Effects 0.000 description 11
230000035515 penetration Effects 0.000 description 11
102000004877 Insulin Human genes 0.000 description 10
108090001061 Insulin Proteins 0.000 description 10
230000008020 evaporation Effects 0.000 description 10
238000002474 experimental method Methods 0.000 description 10
229940125396 insulin Drugs 0.000 description 10
239000012071 phase Substances 0.000 description 10
230000037317 transdermal delivery Effects 0.000 description 10
RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 9
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
229960000907 methylthioninium chloride Drugs 0.000 description 9
230000032258 transport Effects 0.000 description 9
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 8
238000005259 measurement Methods 0.000 description 8
UQDUPQYQJKYHQI-UHFFFAOYSA-N methyl laurate Chemical compound CCCCCCCCCCCC(=O)OC UQDUPQYQJKYHQI-UHFFFAOYSA-N 0.000 description 8
239000002904 solvent Substances 0.000 description 8
NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 7
230000015572 biosynthetic process Effects 0.000 description 7
239000000356 contaminant Substances 0.000 description 7
238000001514 detection method Methods 0.000 description 7
238000000605 extraction Methods 0.000 description 7
238000000338 in vitro Methods 0.000 description 7
230000003993 interaction Effects 0.000 description 7
229960004194 lidocaine Drugs 0.000 description 7
239000000463 material Substances 0.000 description 7
230000004044 response Effects 0.000 description 7
231100000245 skin permeability Toxicity 0.000 description 7
238000004458 analytical method Methods 0.000 description 6
238000011161 development Methods 0.000 description 6
230000018109 developmental process Effects 0.000 description 6
210000000245 forearm Anatomy 0.000 description 6
238000009472 formulation Methods 0.000 description 6
238000001727 in vivo Methods 0.000 description 6
230000001939 inductive effect Effects 0.000 description 6
238000002347 injection Methods 0.000 description 6
239000007924 injection Substances 0.000 description 6
230000033001 locomotion Effects 0.000 description 6
230000007246 mechanism Effects 0.000 description 6
230000005855 radiation Effects 0.000 description 6
230000000007 visual effect Effects 0.000 description 6
241001465754 Metazoa Species 0.000 description 5
-1 alcohol ester Chemical class 0.000 description 5
206010012601 diabetes mellitus Diseases 0.000 description 5
239000003961 penetration enhancing agent Substances 0.000 description 5
238000005070 sampling Methods 0.000 description 5
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
230000002745 absorbent Effects 0.000 description 4
239000002250 absorbent Substances 0.000 description 4
239000013543 active substance Substances 0.000 description 4
230000008901 benefit Effects 0.000 description 4
229910002056 binary alloy Inorganic materials 0.000 description 4
239000000969 carrier Substances 0.000 description 4
238000006073 displacement reaction Methods 0.000 description 4
238000005516 engineering process Methods 0.000 description 4
210000001339 epidermal cell Anatomy 0.000 description 4
239000011521 glass Substances 0.000 description 4
230000001976 improved effect Effects 0.000 description 4
230000006872 improvement Effects 0.000 description 4
238000011835 investigation Methods 0.000 description 4
229910052742 iron Inorganic materials 0.000 description 4
230000001678 irradiating effect Effects 0.000 description 4
210000004400 mucous membrane Anatomy 0.000 description 4
230000008058 pain sensation Effects 0.000 description 4
239000000047 product Substances 0.000 description 4
230000036962 time dependent Effects 0.000 description 4
238000009834 vaporization Methods 0.000 description 4
230000008016 vaporization Effects 0.000 description 4
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
241001310793 Podium Species 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
230000004913 activation Effects 0.000 description 3
239000002390 adhesive tape Substances 0.000 description 3
210000001124 body fluid Anatomy 0.000 description 3
239000010839 body fluid Substances 0.000 description 3
230000001276 controlling effect Effects 0.000 description 3
210000000736 corneocyte Anatomy 0.000 description 3
238000010586 diagram Methods 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
239000003792 electrolyte Substances 0.000 description 3
230000002708 enhancing effect Effects 0.000 description 3
210000003811 finger Anatomy 0.000 description 3
230000036571 hydration Effects 0.000 description 3
238000006703 hydration reaction Methods 0.000 description 3
MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical compound [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 description 3
229960004657 indocyanine green Drugs 0.000 description 3
150000002632 lipids Chemical group 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
230000009467 reduction Effects 0.000 description 3
238000000926 separation method Methods 0.000 description 3
238000005476 soldering Methods 0.000 description 3
230000003595 spectral effect Effects 0.000 description 3
230000002123 temporal effect Effects 0.000 description 3
210000003813 thumb Anatomy 0.000 description 3
230000000472 traumatic effect Effects 0.000 description 3
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 2
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
108091006146 Channels Proteins 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
239000005642 Oleic acid Substances 0.000 description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
239000004820 Pressure-sensitive adhesive Substances 0.000 description 2
241000283984 Rodentia Species 0.000 description 2
206010040880 Skin irritation Diseases 0.000 description 2
239000004809 Teflon Substances 0.000 description 2
229920006362 Teflon® Polymers 0.000 description 2
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
206010052428 Wound Diseases 0.000 description 2
238000002835 absorbance Methods 0.000 description 2
239000002253 acid Substances 0.000 description 2
230000009471 action Effects 0.000 description 2
230000002411 adverse Effects 0.000 description 2
230000000202 analgesic effect Effects 0.000 description 2
229940035676 analgesics Drugs 0.000 description 2
239000000730 antalgic agent Substances 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
239000012620 biological material Substances 0.000 description 2
230000037396 body weight Effects 0.000 description 2
238000009835 boiling Methods 0.000 description 2
RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
238000004364 calculation method Methods 0.000 description 2
239000000812 cholinergic antagonist Substances 0.000 description 2
238000005345 coagulation Methods 0.000 description 2
230000015271 coagulation Effects 0.000 description 2
XCJYREBRNVKWGJ-UHFFFAOYSA-N copper(II) phthalocyanine Chemical compound [Cu+2].C12=CC=CC=C2C(N=C2[N-]C(C3=CC=CC=C32)=N2)=NC1=NC([C]1C=CC=CC1=1)=NC=1N=C1[C]3C=CC=CC3=C2[N-]1 XCJYREBRNVKWGJ-UHFFFAOYSA-N 0.000 description 2
230000002596 correlated effect Effects 0.000 description 2
230000000875 corresponding effect Effects 0.000 description 2
230000008878 coupling Effects 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
238000005859 coupling reaction Methods 0.000 description 2
CEJANLKHJMMNQB-UHFFFAOYSA-M cryptocyanin Chemical compound [I-].C12=CC=CC=C2N(CC)C=CC1=CC=CC1=CC=[N+](CC)C2=CC=CC=C12 CEJANLKHJMMNQB-UHFFFAOYSA-M 0.000 description 2
230000001351 cycling effect Effects 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
238000000151 deposition Methods 0.000 description 2
150000002009 diols Chemical class 0.000 description 2
210000000624 ear auricle Anatomy 0.000 description 2
230000005684 electric field Effects 0.000 description 2
230000005284 excitation Effects 0.000 description 2
239000000499 gel Substances 0.000 description 2
RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 description 2
238000005534 hematocrit Methods 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
239000002085 irritant Substances 0.000 description 2
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
238000000608 laser ablation Methods 0.000 description 2
239000003550 marker Substances 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
230000005012 migration Effects 0.000 description 2
238000013508 migration Methods 0.000 description 2
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
230000000149 penetrating effect Effects 0.000 description 2
230000008823 permeabilization Effects 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
150000004032 porphyrins Chemical class 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 2
238000011160 research Methods 0.000 description 2
210000004927 skin cell Anatomy 0.000 description 2
230000036556 skin irritation Effects 0.000 description 2
231100000475 skin irritation Toxicity 0.000 description 2
230000001954 sterilising effect Effects 0.000 description 2
238000004659 sterilization and disinfection Methods 0.000 description 2
150000003431 steroids Chemical class 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
239000000725 suspension Substances 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
230000000451 tissue damage Effects 0.000 description 2
231100000827 tissue damage Toxicity 0.000 description 2
238000013271 transdermal drug delivery Methods 0.000 description 2
230000001052 transient effect Effects 0.000 description 2
229940124549 vasodilator Drugs 0.000 description 2
239000003071 vasodilator agent Substances 0.000 description 2
ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
WDQFELCEOPFLCZ-UHFFFAOYSA-N 1-(2-hydroxyethyl)pyrrolidin-2-one Chemical compound OCCN1CCCC1=O WDQFELCEOPFLCZ-UHFFFAOYSA-N 0.000 description 1
AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
ARIWANIATODDMH-AWEZNQCLSA-N 1-lauroyl-sn-glycerol Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)CO ARIWANIATODDMH-AWEZNQCLSA-N 0.000 description 1
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
BHIZVZJETFVJMJ-UHFFFAOYSA-N 2-hydroxypropyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(C)O BHIZVZJETFVJMJ-UHFFFAOYSA-N 0.000 description 1
ODHCTXKNWHHXJC-UHFFFAOYSA-N 5-oxoproline Chemical compound OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
229940127291 Calcium channel antagonist Drugs 0.000 description 1
229920000298 Cellophane Polymers 0.000 description 1
108010062580 Concanavalin A Proteins 0.000 description 1
PHOQVHQSTUBQQK-SQOUGZDYSA-N D-glucono-1,5-lactone Chemical compound OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O PHOQVHQSTUBQQK-SQOUGZDYSA-N 0.000 description 1
LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
229910052691 Erbium Inorganic materials 0.000 description 1
206010016334 Feeling hot Diseases 0.000 description 1
241000427324 Glinus Species 0.000 description 1
239000004366 Glucose oxidase Substances 0.000 description 1
108010015776 Glucose oxidase Proteins 0.000 description 1
208000013016 Hypoglycemia Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
ARIWANIATODDMH-UHFFFAOYSA-N Lauric acid monoglyceride Natural products CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 1
108090001090 Lectins Proteins 0.000 description 1
102000004856 Lectins Human genes 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
208000000114 Pain Threshold Diseases 0.000 description 1
102000003992 Peroxidases Human genes 0.000 description 1
208000003251 Pruritus Diseases 0.000 description 1
229940123452 Rapid-acting insulin Drugs 0.000 description 1
108010026951 Short-Acting Insulin Proteins 0.000 description 1
206010040844 Skin exfoliation Diseases 0.000 description 1
239000000150 Sympathomimetic Substances 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
210000000683 abdominal cavity Anatomy 0.000 description 1
239000006096 absorbing agent Substances 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
239000012790 adhesive layer Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
239000002160 alpha blocker Substances 0.000 description 1
229940124308 alpha-adrenoreceptor antagonist Drugs 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
230000003321 amplification Effects 0.000 description 1
230000003444 anaesthetic effect Effects 0.000 description 1
239000002269 analeptic agent Substances 0.000 description 1
230000000578 anorexic effect Effects 0.000 description 1
230000000507 anthelmentic effect Effects 0.000 description 1
229940124339 anthelmintic agent Drugs 0.000 description 1
239000000921 anthelmintic agent Substances 0.000 description 1
230000003288 anthiarrhythmic effect Effects 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000001088 anti-asthma Effects 0.000 description 1
230000001142 anti-diarrhea Effects 0.000 description 1
230000002686 anti-diuretic effect Effects 0.000 description 1
230000002924 anti-infective effect Effects 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
230000002460 anti-migrenic effect Effects 0.000 description 1
230000001062 anti-nausea Effects 0.000 description 1
230000001754 anti-pyretic effect Effects 0.000 description 1
230000002921 anti-spasmodic effect Effects 0.000 description 1
239000003416 antiarrhythmic agent Substances 0.000 description 1
239000000924 antiasthmatic agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
229940125681 anticonvulsant agent Drugs 0.000 description 1
239000001961 anticonvulsive agent Substances 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
239000003472 antidiabetic agent Substances 0.000 description 1
229940125708 antidiabetic agent Drugs 0.000 description 1
229940124538 antidiuretic agent Drugs 0.000 description 1
229940125715 antihistaminic agent Drugs 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
229940030600 antihypertensive agent Drugs 0.000 description 1
229960005475 antiinfective agent Drugs 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
229940034982 antineoplastic agent Drugs 0.000 description 1
239000000939 antiparkinson agent Substances 0.000 description 1
239000000164 antipsychotic agent Substances 0.000 description 1
229940005529 antipsychotics Drugs 0.000 description 1
239000002221 antipyretic Substances 0.000 description 1
229940125716 antipyretic agent Drugs 0.000 description 1
229940124575 antispasmodic agent Drugs 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
229940121357 antivirals Drugs 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
238000003491 array Methods 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
238000003556 assay Methods 0.000 description 1
238000005452 bending Methods 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
239000002876 beta blocker Substances 0.000 description 1
229940097320 beta blocking agent Drugs 0.000 description 1
229940064804 betadine Drugs 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000012472 biological sample Substances 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
239000001045 blue dye Substances 0.000 description 1
229960001948 caffeine Drugs 0.000 description 1
VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000000480 calcium channel blocker Substances 0.000 description 1
238000004422 calculation algorithm Methods 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
239000012876 carrier material Substances 0.000 description 1
230000005779 cell damage Effects 0.000 description 1
208000037887 cell injury Diseases 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
230000000739 chaotic effect Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
229930002875 chlorophyll Natural products 0.000 description 1
235000019804 chlorophyll Nutrition 0.000 description 1
ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
235000019504 cigarettes Nutrition 0.000 description 1
230000004087 circulation Effects 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
238000012937 correction Methods 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
239000002537 cosmetic Substances 0.000 description 1
229940037530 cough and cold preparations Drugs 0.000 description 1
239000013078 crystal Substances 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
238000013480 data collection Methods 0.000 description 1
239000000850 decongestant Substances 0.000 description 1
229940124581 decongestants Drugs 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
230000018044 dehydration Effects 0.000 description 1
238000006297 dehydration reaction Methods 0.000 description 1
230000001934 delay Effects 0.000 description 1
230000008021 deposition Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
230000035618 desquamation Effects 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical group CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
239000002934 diuretic Substances 0.000 description 1
229940030606 diuretics Drugs 0.000 description 1
HJXPPCPJEYUQFQ-HNNXBMFYSA-N dodecyl (2s)-5-oxopyrrolidine-2-carboxylate Chemical compound CCCCCCCCCCCCOC(=O)[C@@H]1CCC(=O)N1 HJXPPCPJEYUQFQ-HNNXBMFYSA-N 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
230000005611 electricity Effects 0.000 description 1
230000005672 electromagnetic field Effects 0.000 description 1
230000005670 electromagnetic radiation Effects 0.000 description 1
238000005370 electroosmosis Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
238000000295 emission spectrum Methods 0.000 description 1
238000004836 empirical method Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
UYAHIZSMUZPPFV-UHFFFAOYSA-N erbium Chemical compound [Er] UYAHIZSMUZPPFV-UHFFFAOYSA-N 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
229960005309 estradiol Drugs 0.000 description 1
229930182833 estradiol Natural products 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
210000001723 extracellular space Anatomy 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
150000004665 fatty acids Chemical group 0.000 description 1
230000008014 freezing Effects 0.000 description 1
238000007710 freezing Methods 0.000 description 1
235000015203 fruit juice Nutrition 0.000 description 1
210000001156 gastric mucosa Anatomy 0.000 description 1
235000021474 generally recognized As safe (food) Nutrition 0.000 description 1
235000021473 generally recognized as safe (food ingredients) Nutrition 0.000 description 1
235000012209 glucono delta-lactone Nutrition 0.000 description 1
229960003681 gluconolactone Drugs 0.000 description 1
229940116332 glucose oxidase Drugs 0.000 description 1
235000019420 glucose oxidase Nutrition 0.000 description 1
150000002314 glycerols Chemical class 0.000 description 1
150000003278 haem Chemical class 0.000 description 1
238000003505 heat denaturation Methods 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
239000003326 hypnotic agent Substances 0.000 description 1
230000000147 hypnotic effect Effects 0.000 description 1
238000005286 illumination Methods 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
239000007943 implant Substances 0.000 description 1
230000006698 induction Effects 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
238000009413 insulation Methods 0.000 description 1
239000012212 insulator Substances 0.000 description 1
239000011630 iodine Substances 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
230000037427 ion transport Effects 0.000 description 1
230000001788 irregular Effects 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
231100000021 irritant Toxicity 0.000 description 1
230000000622 irritating effect Effects 0.000 description 1
230000003780 keratinization Effects 0.000 description 1
210000002510 keratinocyte Anatomy 0.000 description 1
229910052743 krypton Inorganic materials 0.000 description 1
DNNSSWSSYDEUBZ-UHFFFAOYSA-N krypton atom Chemical compound [Kr] DNNSSWSSYDEUBZ-UHFFFAOYSA-N 0.000 description 1
238000011545 laboratory measurement Methods 0.000 description 1
239000011133 lead Substances 0.000 description 1
239000002523 lectin Substances 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000007791 liquid phase Substances 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
239000003589 local anesthetic agent Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
238000013178 mathematical model Methods 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
229960004503 metoclopramide Drugs 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
210000002200 mouth mucosa Anatomy 0.000 description 1
229940035363 muscle relaxants Drugs 0.000 description 1
239000003158 myorelaxant agent Substances 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
210000001640 nerve ending Anatomy 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
238000010943 off-gassing Methods 0.000 description 1
239000003921 oil Substances 0.000 description 1
229940055577 oleyl alcohol Drugs 0.000 description 1
XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
239000013307 optical fiber Substances 0.000 description 1
238000005457 optimization Methods 0.000 description 1
235000015205 orange juice Nutrition 0.000 description 1
238000013021 overheating Methods 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
229940094443 oxytocics prostaglandins Drugs 0.000 description 1
230000008533 pain sensitivity Effects 0.000 description 1
230000037040 pain threshold Effects 0.000 description 1
206010033675 panniculitis Diseases 0.000 description 1
230000002445 parasympatholytic effect Effects 0.000 description 1
239000013618 particulate matter Substances 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000012466 permeate Substances 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
235000019271 petrolatum Nutrition 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
239000002831 pharmacologic agent Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
239000000049 pigment Substances 0.000 description 1
239000004417 polycarbonate Substances 0.000 description 1
229920000515 polycarbonate Polymers 0.000 description 1
150000004291 polyenes Polymers 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229960003975 potassium Drugs 0.000 description 1
239000003450 potassium channel blocker Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
238000007639 printing Methods 0.000 description 1
239000000583 progesterone congener Substances 0.000 description 1
229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 description 1
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
229940026235 propylene glycol monolaurate Drugs 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
230000003304 psychophysiological effect Effects 0.000 description 1
239000003368 psychostimulant agent Substances 0.000 description 1
230000001007 puffing effect Effects 0.000 description 1
230000000541 pulsatile effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
150000003873 salicylate salts Chemical class 0.000 description 1
238000007789 sealing Methods 0.000 description 1
229940125723 sedative agent Drugs 0.000 description 1
239000000932 sedative agent Substances 0.000 description 1
238000004062 sedimentation Methods 0.000 description 1
239000004065 semiconductor Substances 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
238000010008 shearing Methods 0.000 description 1
230000035939 shock Effects 0.000 description 1
230000011664 signaling Effects 0.000 description 1
230000037380 skin damage Effects 0.000 description 1
238000002791 soaking Methods 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
238000010186 staining Methods 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
210000000439 stratum lucidum Anatomy 0.000 description 1
210000004304 subcutaneous tissue Anatomy 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
230000001975 sympathomimetic effect Effects 0.000 description 1
229940064707 sympathomimetics Drugs 0.000 description 1
210000000225 synapse Anatomy 0.000 description 1
229920002994 synthetic fiber Polymers 0.000 description 1
238000002207 thermal evaporation Methods 0.000 description 1
229940098465 tincture Drugs 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
230000007704 transition Effects 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
229910052721 tungsten Inorganic materials 0.000 description 1
239000010937 tungsten Substances 0.000 description 1
239000012808 vapor phase Substances 0.000 description 1
239000005526 vasoconstrictor agent Substances 0.000 description 1
238000012795 verification Methods 0.000 description 1
239000012905 visible particle Substances 0.000 description 1
238000010792 warming Methods 0.000 description 1
239000001993 wax Substances 0.000 description 1
229910052724 xenon Inorganic materials 0.000 description 1
FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/14507—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue specially adapted for measuring characteristics of body fluids other than blood
- A61B5/1451—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue specially adapted for measuring characteristics of body fluids other than blood for interstitial fluid
- A61B5/14514—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue specially adapted for measuring characteristics of body fluids other than blood for interstitial fluid using means for aiding extraction of interstitial fluid, e.g. microneedles or suction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B10/00—Instruments for taking body samples for diagnostic purposes; Other methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determination; Throat striking implements
- A61B10/0045—Devices for taking samples of body liquids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0047—Sonopheresis, i.e. ultrasonically-enhanced transdermal delivery, electroporation of a pharmacologically active agent
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/32—Surgical cutting instruments
- A61B17/3203—Fluid jet cutting instruments
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/18—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
- A61B18/20—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/18—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
- A61B18/20—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser
- A61B18/203—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser applying laser energy to the outside of the body
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B2017/00017—Electrical control of surgical instruments
- A61B2017/00137—Details of operation mode
- A61B2017/00154—Details of operation mode pulsed
- A61B2017/00172—Pulse trains, bursts, intermittent continuous operation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B2017/00743—Type of operation; Specification of treatment sites
- A61B2017/00747—Dermatology
- A61B2017/00761—Removing layer of skin tissue, e.g. wrinkles, scars or cancerous tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B2017/00743—Type of operation; Specification of treatment sites
- A61B2017/00747—Dermatology
- A61B2017/00765—Decreasing the barrier function of skin tissue by radiated energy, e.g. using ultrasound, using laser for skin perforation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00315—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
- A61B2018/00452—Skin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00315—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
- A61B2018/00452—Skin
- A61B2018/0047—Upper parts of the skin, e.g. skin peeling or treatment of wrinkles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/1468—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means
- A61B5/1486—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means using enzyme electrodes, e.g. with immobilised oxidase
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M2037/0007—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin having means for enhancing the permeation of substances through the epidermis, e.g. using suction or depression, electric or magnetic fields, sound waves or chemical agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0092—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin using ultrasonic, sonic or infrasonic vibrations, e.g. phonophoresis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Surgery (AREA)
Heart & Thoracic Surgery (AREA)
Biomedical Technology (AREA)
Engineering & Computer Science (AREA)
Pathology (AREA)
Medical Informatics (AREA)
Dermatology (AREA)
Optics & Photonics (AREA)
Hematology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Measuring And Recording Apparatus For Diagnosis (AREA)
Surgical Instruments (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Laser Surgery Devices (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Media Introduction/Drainage Providing Device (AREA)

NO19980878A 1995-08-29 1998-02-27 Mikroporering av menneskehud for medikamentavlevering og overvåkningsanvendelser NO334437B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US52054795A	1995-08-29	1995-08-29
US804395P	1995-10-30	1995-10-30
PCT/US1996/013865 WO1997007734A1 (fr)	1995-08-29	1996-08-29	Realisation de micropores sur la peau humaine pour l'administration de medicaments et les applications de monitorage

Publications (3)

Publication Number	Publication Date
NO980878D0 NO980878D0 (no)	1998-02-27
NO980878L NO980878L (no)	1998-04-27
NO334437B1 true NO334437B1 (no)	2014-03-03

Family

ID=26677684

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19980878A NO334437B1 (no)	1995-08-29	1998-02-27	Mikroporering av menneskehud for medikamentavlevering og overvåkningsanvendelser

Country Status (13)

Country	Link
EP (1)	EP0858285A4 (fr)
JP (2)	JP3899427B2 (fr)
CN (1)	CN1174713C (fr)
AU (1)	AU707065B2 (fr)
BR (1)	BR9610012A (fr)
CA (1)	CA2199002C (fr)
ES (1)	ES2536459T3 (fr)
GB (1)	GB2307414B (fr)
IL (1)	IL123379A (fr)
NO (1)	NO334437B1 (fr)
PT (1)	PT1563788E (fr)
TR (1)	TR199800347T1 (fr)
WO (1)	WO1997007734A1 (fr)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6315772B1 (en)	1993-09-24	2001-11-13	Transmedica International, Inc.	Laser assisted pharmaceutical delivery and fluid removal
DE69719761T2 (de)	1996-06-18	2003-12-18	Alza Corp., Palo Alto	Vorrichtung zur verbesserung der transdermalen verabreichung von medikamenten oder der abnahme von körperflüssigkeiten
DE69722414T2 (de) *	1996-07-03	2004-05-19	Altea Therapeutics Corp.	Mehrfache mechanische mikroperforierung von haut oder schleimhäuten
JP4054381B2 (ja) *	1996-09-17	2008-02-27	デカ・プロダクツ・リミテッド・パートナーシップ	移送による薬伝達システム
US20060002949A1 (en)	1996-11-14	2006-01-05	Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc.	Transcutaneous immunization without heterologous adjuvant
US6797276B1 (en)	1996-11-14	2004-09-28	The United States Of America As Represented By The Secretary Of The Army	Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US5980898A (en)	1996-11-14	1999-11-09	The United States Of America As Represented By The U.S. Army Medical Research & Material Command	Adjuvant for transcutaneous immunization
DK1314400T3 (da) *	1996-12-31	2007-10-15	Altea Therapeutics Corp	Mikroporering af væv til levering af bioaktive midler
US6527716B1 (en)	1997-12-30	2003-03-04	Altea Technologies, Inc.	Microporation of tissue for delivery of bioactive agents
US6027496A (en) *	1997-03-25	2000-02-22	Abbott Laboratories	Removal of stratum corneum by means of light
JP4338307B2 (ja)	1997-10-21	2009-10-07	アボット・ラボラトリーズ	間質液を収集する装置および方法
US6155992A (en) *	1997-12-02	2000-12-05	Abbott Laboratories	Method and apparatus for obtaining interstitial fluid for diagnostic tests
US6918901B1 (en)	1997-12-10	2005-07-19	Felix Theeuwes	Device and method for enhancing transdermal agent flux
AU739616B2 (en) *	1997-12-11	2001-10-18	Alza Corporation	Device for enhancing transdermal agent flux
AU757192B2 (en) *	1997-12-11	2003-02-06	Alza Corporation	Device for enhancing transdermal agent flux
JP2001525227A (ja)	1997-12-11	2001-12-11	アルザ・コーポレーション	経皮的薬剤流量を高めるための装置
US6530915B1 (en)	1998-03-06	2003-03-11	Spectrx, Inc.	Photothermal structure for biomedical applications, and method therefor
US6173202B1 (en) *	1998-03-06	2001-01-09	Spectrx, Inc.	Method and apparatus for enhancing flux rates of a fluid in a microporated biological tissue
AU2989399A (en) *	1998-03-06	1999-09-20	Altea Technologies, Inc.	Integrated poration, harvesting and analysis device, and method therefor
US6091975A (en) *	1998-04-01	2000-07-18	Alza Corporation	Minimally invasive detecting device
US6569157B1 (en) *	1998-05-18	2003-05-27	Abbott Laboratories	Removal of stratum corneum by means of light
US7344499B1 (en)	1998-06-10	2008-03-18	Georgia Tech Research Corporation	Microneedle device for extraction and sensing of bodily fluids
US6077660A (en) *	1998-06-10	2000-06-20	Abbott Laboratories	Diagnostic assay requiring a small sample of biological fluid
US6503231B1 (en)	1998-06-10	2003-01-07	Georgia Tech Research Corporation	Microneedle device for transport of molecules across tissue
US6352506B1 (en)	1998-07-14	2002-03-05	Altea Technologies	Controlled removal of biological membrane by pyrotechnic charge for transmembrane transport
US7384396B2 (en)	1998-07-21	2008-06-10	Spectrx Inc.	System and method for continuous analyte monitoring
MXPA01000698A (es) *	1998-07-21	2002-04-08	Spectrx Inc	Sistema y metodo para el monitoreo de analito continuo.
IL141774A0 (en) *	1998-09-04	2002-03-10	Powderject Res Ltd	Monitoring methods using particle delivery methods
US6468229B1 (en)	1998-10-20	2002-10-22	Abbott Laboratories	Apparatus and method for the collection of interstitial fluids
US6708060B1 (en)	1998-11-09	2004-03-16	Transpharma Ltd.	Handheld apparatus and method for transdermal drug delivery and analyte extraction
US6597946B2 (en)	1998-11-09	2003-07-22	Transpharma Ltd.	Electronic card for transdermal drug delivery and analyte extraction
US6148232A (en)	1998-11-09	2000-11-14	Elecsys Ltd.	Transdermal drug delivery and analyte extraction
US6611706B2 (en)	1998-11-09	2003-08-26	Transpharma Ltd.	Monopolar and bipolar current application for transdermal drug delivery and analyte extraction
US6743211B1 (en)	1999-11-23	2004-06-01	Georgia Tech Research Corporation	Devices and methods for enhanced microneedle penetration of biological barriers
US6611707B1 (en)	1999-06-04	2003-08-26	Georgia Tech Research Corporation	Microneedle drug delivery device
ES2260021T3 (es) *	1999-06-08	2006-11-01	Altea Therapeutics Corporation	Aparatos para la microporacion de membranas biologicas utilizando dispositivos de interfaz de tejido de pelicula delgada, y su metodo.
US20030078499A1 (en)	1999-08-12	2003-04-24	Eppstein Jonathan A.	Microporation of tissue for delivery of bioactive agents
US6355054B1 (en) *	1999-11-05	2002-03-12	Ceramoptec Industries, Inc.	Laser system for improved transbarrier therapeutic radiation delivery
DE19963034A1 (de)	1999-12-24	2001-06-28	Roche Diagnostics Gmbh	System zur verbesserten Bestimmung des Glukosespiegels anhand von Messungen in interstitieller Flüssigkeit
IL136008A0 (en)	2000-05-07	2001-05-20	Elecsys Ltd	Electrically-mediated transdermal drug injection
US6706032B2 (en)	2000-06-08	2004-03-16	Massachusetts Institute Of Technology	Localized molecular and ionic transport to and from tissues
US7597692B2 (en)	2000-06-08	2009-10-06	Massachusetts Institute Of Technology	Microscission processes and procedures
AUPR044000A0 (en) *	2000-09-28	2000-10-26	Norwood Abbey Ltd	Diagnostic device
US6537243B1 (en)	2000-10-12	2003-03-25	Abbott Laboratories	Device and method for obtaining interstitial fluid from a patient for diagnostic tests
US6882884B1 (en)	2000-10-13	2005-04-19	Soundskin, L.L.C.	Process for the stimulation of production of extracellular dermal proteins in human tissue
US6733493B2 (en) *	2000-11-16	2004-05-11	Innotech Usa, Inc.	Laser skin perforator
WO2002064193A2 (fr)	2000-12-14	2002-08-22	Georgia Tech Research Corporation	Appareils a microaiguilles et fabrication
US7027478B2 (en)	2000-12-21	2006-04-11	Biovalve Technologies, Inc.	Microneedle array systems
DK1372708T3 (da)	2001-02-13	2008-10-20	Us Gov Sec Army	Vaccine til transkutan immunisering mod rejsediarre
JP4704583B2 (ja) *	2001-02-28	2011-06-15	有限会社開発顧問室	パッチテスト用シート
US6790179B2 (en)	2001-08-01	2004-09-14	Johnson & Johnson Consumer Companies, Inc.	Method of examining and diagnosing skin health
US6855117B2 (en)	2001-08-01	2005-02-15	Johnson & Johnson Consumer Companies, Inc.	Method of treating the skin of a subject
US6840910B2 (en)	2001-08-01	2005-01-11	Johnson & Johnson Consumer Companies, Inc.	Method of distributing skin care products
AU2002327675A1 (en)	2001-09-19	2003-04-01	Biovalve Technologies, Inc.	Microneedles, microneedle arrays, and systems and methods relating to same
US8920375B2 (en)	2001-09-21	2014-12-30	Valeritas, Inc.	Gas pressure actuated microneedle arrays, and systems and methods relating to same
EP2319577B1 (fr)	2001-11-07	2017-03-15	Syneron Medical Ltd.	Système intégré d'administration transdermale de médicaments
US9918665B2 (en)	2002-03-11	2018-03-20	Nitto Denko Corporation	Transdermal porator and patch system and method for using same
AU2003220143A1 (en)	2002-03-11	2003-09-29	Altea Therapeutics Corporation	Transdermal integrated actuator device, methods of making and using same
WO2003089043A2 (fr)	2002-04-19	2003-10-30	Transpharma Medical Ltd.	Administration de medicaments et extraction d'analyte par voie transdermique a l'aide d'un appareil tenu a la main
IL152575A (en)	2002-10-31	2008-12-29	Transpharma Medical Ltd	A skin-to-skin transmission system of water-insoluble drugs
IL152573A (en)	2002-10-31	2009-11-18	Transpharma Medical Ltd	A system for the transmission through the skin of a medical preparation against vomiting and nausea
IL152574A (en)	2002-10-31	2009-09-22	Transpharma Medical Ltd	A system for passing through the skin of dry items or dried medicines
US8133505B2 (en)	2002-10-31	2012-03-13	Transpharma Medical Ltd.	Transdermal delivery system for dried particulate or lyophilized medications
US7662404B2 (en)	2002-10-31	2010-02-16	Transpharma Medical Ltd.	Transdermal delivery system for dried particulate or lyophilized peptides and polypeptides
US7383084B2 (en)	2002-10-31	2008-06-03	Transpharma Medical Ltd.	Transdermal delivery system for dried particulate or lyophilized medications
US7258673B2 (en)	2003-06-06	2007-08-21	Lifescan, Inc	Devices, systems and methods for extracting bodily fluid and monitoring an analyte therein
US8016811B2 (en)	2003-10-24	2011-09-13	Altea Therapeutics Corporation	Method for transdermal delivery of permeant substances
WO2005042054A2 (fr) *	2003-10-24	2005-05-12	Alza Corporation	Procede et systeme de pretraitement permettant d'ameliorer l'administration transdermique de medicaments
EP1680057A4 (fr) *	2003-10-24	2007-10-31	Alza Corp	Dispositif et procede d'amelioration de l'administration transdermique de medicament
AU2005299759A1 (en)	2004-10-21	2006-05-04	Bayer Healthcare Llc	Method of determining the concentration of an analyte in a body fluid and system therefor
JP2006326147A (ja) *	2005-05-30	2006-12-07	Shingo Wakamatsu	レーザー治療装置
TWI419717B (zh) *	2005-06-17	2013-12-21	Altea Therapeutics Corp	滲透傳送系統及其使用方法
JP5011935B2 (ja) *	2006-10-11	2012-08-29	パナソニック株式会社	血液検査装置
JP5011936B2 (ja) *	2006-10-11	2012-08-29	パナソニック株式会社	血液検査装置
US8010188B2 (en)	2006-11-14	2011-08-30	Kagoshima University	Drug injecting device
RU2328739C1 (ru) *	2007-02-26	2008-07-10	Айрат Анварович Халиков	Способ определения целостности клеточных мембран биологической ткани трупа
KR101211252B1 (ko) *	2007-04-27	2012-12-12	에코 테라퓨틱스, 인크.	경피 피분석물 감지 또는 경피 약제 전달용 피부 침투장치
CA2704740C (fr)	2007-10-09	2016-05-17	Transpharma Ltd.	Fixation magnetique d'un timbre transdermique
CA2696227A1 (fr)	2007-10-17	2009-04-23	Transpharma Medical Ltd.	Verification de la vitesse de dissolution
WO2009060701A1 (fr) *	2007-11-06	2009-05-14	Konica Minolta Opto, Inc.	Appareil de formation de micro-ouvertures et systeme de collecte de liquide corporel mettant en œuvre ledit appareil
MX2010006062A (es)	2007-12-05	2010-09-14	Syneron Medical Ltd	Aplicador desechable de energia electromagnetica y metodo para su uso.
GB0811856D0 (en)	2008-06-27	2008-07-30	Ucl Business Plc	Magnetic microbubbles, methods of preparing them and their uses
US8606366B2 (en)	2009-02-18	2013-12-10	Syneron Medical Ltd.	Skin treatment apparatus for personal use and method for using same
US20100256466A1 (en) *	2009-04-02	2010-10-07	Avraham Shekalim	Metabolite Management System
WO2011013118A2 (fr)	2009-07-27	2011-02-03	Slatkine Michael	Procédés et dispositifs d'ablation de tissu
PT105635B (pt) *	2011-04-19	2014-04-11	Univ De Coimbra	Dispositivo para a administração eficiente de compostos na pele ou barreiras biológicas, ou através dessas, usando filmes finos absorventes de luz
CN111529048B (zh)	2013-12-18	2024-03-26	诺服塞尔有限公司	汽化组织的设备及方法
EP3193761B1 (fr)	2014-09-15	2021-03-24	Novoxel Ltd.	Procédés de production de dispositifs pour la vaporisation et la compression thermiques de tissu
CN107205771A (zh) *	2014-09-15	2017-09-26	诺服塞尔有限公司	用于热外科汽化及切割组织的方法和装置
EP3265168A1 (fr) *	2015-03-03	2018-01-10	Guided Therapy Systems, L.L.C.	Procédés et systèmes pour l'administration assistée par ultrasons d'un médicament dans un tissu
JP6876045B2 (ja) *	2015-12-15	2021-05-26	コーニンクレッカフィリップスエヌヴェＫｏｎｉｎｋｌｉｊｋｅＰｈｉｌｉｐｓＮ．Ｖ．	表面処理装置及び方法
WO2017123954A1 (fr) *	2016-01-15	2017-07-20	University Of Cincinnati	Dispositifs et procédés d'électroporation avancés pour accès d'analyte dans des biofluides
AU2017280014B2 (en) *	2016-06-20	2022-05-26	University Of North Texas	Laser-assisted machining (LAM) of non-monolithic composite bone material
FI127811B (en) *	2016-11-21	2019-03-15	Helsingin Yliopisto	Device for sampling one or more analytes
EP3361402B1 (fr) *	2017-02-14	2024-12-04	Roche Diabetes Care GmbH	Une méthode mise en oeuvre par ordinateur et un dispositif portable pour analyser les données de surveillance du glucose indicatives d'un taux de glucose dans un liquide corporel, et un support non transitoire lisible par odinateur
US11441994B2 (en) *	2017-07-27	2022-09-13	Tata Consultancy Services Limited	Method and system for in-silico design of skin electroporation
US20210129136A1 (en) *	2017-08-03	2021-05-06	Fibrotx Oü	Lateral flow assay and device for skin care application
CN109157280A (zh) *	2018-08-10	2019-01-08	重庆大学	不可逆电穿孔组织消融效果动态实时评估设备
CA3242209A1 (fr) *	2018-08-23	2020-02-27	Novocure Gmbh	Utilisation de champs electriques alternatifs pour augmenter la permeabilite de la barriere hemato-encephalique
EP3990063A4 (fr) *	2019-06-28	2023-07-05	PassPort Technologies, Inc.	Procédés et systèmes de commande de la distribution d'énergie à des dispositifs à filament
TWI729670B (zh) *	2019-08-02	2021-06-01	華廣生技股份有限公司	生物感測器之植入裝置
CN110613893A (zh) *	2019-10-31	2019-12-27	南京工业职业技术学院	一种新型励磁线圈
CN111693434B (zh) *	2020-06-19	2024-01-19	中建路桥集团有限公司	一种测试混凝土抗渗性能的实验装置
CN114504373A (zh) *	2020-11-16	2022-05-17	澳美力科技(成都)有限公司	一种新型射频变频美容仪
CN112957124B (zh) *	2021-01-30	2023-08-22	南京理工大学	一种能量靶向调控的离体激光生物组织焊接缝合方法
CN113397698B (zh) *	2021-05-20	2023-04-18	东莞市飞越激光设备有限公司	一种保证高精度和高速度的激光切线装置
CN114343839B (zh) *	2021-12-30	2024-07-23	德州环球之光医疗科技股份有限公司	一种基于可调的螺旋线型激光光斑的治疗图形转换方法
CN116999687B (zh) *	2023-07-19	2024-11-12	河南翔宇医疗设备股份有限公司	一种超声渗透仪以及超声渗透仪输出参数设置装置、介质

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4775361A (en) *	1986-04-10	1988-10-04	The General Hospital Corporation	Controlled removal of human stratum corneum by pulsed laser to enhance percutaneous transport
US4863970A (en) *	1986-11-14	1989-09-05	Theratech, Inc.	Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols
WO1989006555A1 (fr) *	1988-01-21	1989-07-27	Massachusetts Institute Of Technology	Transport de molecules a travers les tissus par electroporation
US5139023A (en) *	1989-06-02	1992-08-18	Theratech Inc.	Apparatus and method for noninvasive blood glucose monitoring
US5016615A (en) *	1990-02-20	1991-05-21	Riverside Research Institute	Local application of medication with ultrasound
US5115805A (en) *	1990-02-23	1992-05-26	Cygnus Therapeutic Systems	Ultrasound-enhanced delivery of materials into and through the skin
GB9014307D0 (en) *	1990-06-27	1990-08-15	Scient Generics Ltd	Method of treatment and compositions therefor
JP3189337B2 (ja) *	1991-11-08	2001-07-16	日本電気株式会社	皮膚角層の除去器具および除去方法
US5344418A (en) *	1991-12-12	1994-09-06	Shahriar Ghaffari	Optical system for treatment of vascular lesions
US5165418B1 (en)	1992-03-02	1999-12-14	Nikola I Tankovich	Blood sampling device and method using a laser
US5246437A (en) *	1992-04-10	1993-09-21	Abela George S	Cell treatment apparatus and method
US5643252A (en) *	1992-10-28	1997-07-01	Venisect, Inc.	Laser perforator
US5279552A (en) *	1993-01-11	1994-01-18	Anton Magnet	Intradermal injection device
US5267985A (en) *	1993-02-11	1993-12-07	Trancell, Inc.	Drug delivery by multiple frequency phonophoresis
US5582184A (en) *	1993-10-13	1996-12-10	Integ Incorporated	Interstitial fluid collection and constituent measurement
US5458140A (en)	1993-11-15	1995-10-17	Non-Invasive Monitoring Company (Nimco)	Enhancement of transdermal monitoring applications with ultrasound and chemical enhancers
US5445611A (en)	1993-12-08	1995-08-29	Non-Invasive Monitoring Company (Nimco)	Enhancement of transdermal delivery with ultrasound and chemical enhancers
AU725269B2 (en) *	1995-07-25	2000-10-12	Massachusetts Institute Of Technology	Enhanced transdermal transport using ultrasound

1996
- 1996-08-29 ES ES05011002.2T patent/ES2536459T3/es not_active Expired - Lifetime
- 1996-08-29 JP JP51055297A patent/JP3899427B2/ja not_active Expired - Lifetime
- 1996-08-29 PT PT50110022T patent/PT1563788E/pt unknown
- 1996-08-29 EP EP96929098A patent/EP0858285A4/fr not_active Withdrawn
- 1996-08-29 CA CA002199002A patent/CA2199002C/fr not_active Expired - Lifetime
- 1996-08-29 IL IL12337996A patent/IL123379A/en not_active IP Right Cessation
- 1996-08-29 GB GB9702766A patent/GB2307414B/en not_active Expired - Lifetime
- 1996-08-29 AU AU68631/96A patent/AU707065B2/en not_active Expired
- 1996-08-29 TR TR1998/00347T patent/TR199800347T1/xx unknown
- 1996-08-29 CN CNB961966718A patent/CN1174713C/zh not_active Expired - Lifetime
- 1996-08-29 BR BR9610012-5A patent/BR9610012A/pt not_active Application Discontinuation
- 1996-08-29 WO PCT/US1996/013865 patent/WO1997007734A1/fr not_active Ceased
1998
- 1998-02-27 NO NO19980878A patent/NO334437B1/no not_active IP Right Cessation
2006
- 2006-02-15 JP JP2006038655A patent/JP2006192285A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
EP0858285A4 (fr)	2000-05-17
IL123379A (en)	2002-04-21
GB2307414B (en)	1998-03-11
GB9702766D0 (en)	1997-04-02
CN1195276A (zh)	1998-10-07
EP0858285A1 (fr)	1998-08-19
TR199800347T1 (xx)	1998-05-21
ES2536459T3 (es)	2015-05-25
IL123379A0 (en)	1998-09-24
JPH11511360A (ja)	1999-10-05
JP3899427B2 (ja)	2007-03-28
NO980878D0 (no)	1998-02-27
AU707065B2 (en)	1999-07-01
HK1009321A1 (en)	1999-05-28
AU6863196A (en)	1997-03-19
PT1563788E (pt)	2015-06-02
CA2199002A1 (fr)	1997-03-01
CN1174713C (zh)	2004-11-10
JP2006192285A (ja)	2006-07-27
CA2199002C (fr)	1999-02-23
GB2307414A (en)	1997-05-28
WO1997007734A1 (fr)	1997-03-06
NO980878L (no)	1998-04-27
BR9610012A (pt)	1999-12-21

Publication	Publication Date	Title
US6142939A (en)	2000-11-07	Microporation of human skin for drug delivery and monitoring applications
AU707065B2 (en)	1999-07-01	Microporation of human skin for drug delivery and monitoring applications
US6527716B1 (en)	2003-03-04	Microporation of tissue for delivery of bioactive agents
US7758561B2 (en)	2010-07-20	Microporation of tissue for delivery of bioactive agents
CA2789115C (fr)	2014-04-29	Formation de micropores sur un tissu pour l'administration d'agents bioactifs
US20020169394A1 (en)	2002-11-14	Integrated tissue poration, fluid harvesting and analysis device, and method therefor
US6419642B1 (en)	2002-07-16	Irradiation enhanced permeation and delivery
CA2329167C (fr)	2008-11-18	Technique et appareil permettant d'accroitre les debits d'un fluide dans un tissu biologique rendu microporeux
US20010050083A1 (en)	2001-12-13	Irradiation enhanced permeation and delivery
EP1563788B1 (fr)	2015-02-18	Microporation de la peau humaine pour l'administration des médicaments et applications de surveillance
RU2209031C2 (ru)	2003-07-27	Формирование микропор в коже человека для доставки лекарственных препаратов и мониторинга
WO2002026148A1 (fr)	2002-04-04	Permeation et prelevement ameliores par irradiation
WO2002026149A1 (fr)	2002-04-04	Penetration et administration ameliorees par irradiation

Legal Events

Date	Code	Title	Description
2014-10-27	CHAD	Change of the owner's name or address (par. 44 patent law, par. patentforskriften)	Owner name: NITTO DENKO CORPORATION, JP
2016-09-05	MK1K	Patent expired